GlaxoSmithKline Plc and Theravance Inc.’s Breo should be approved to treat a lung disorder that is the third-leading cause of death in the U.S.

The companies provided substantial evidence the dry powder inhaler can help keep airways open long-term and reduce exacerbations of chronic obstructive pulmonary disease, a panel of Food and Drug Administration advisers voted today in Silver Spring, Maryland. The FDA is expected to decide whether to approve Breo by May 12.